Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Assist Reprod Genet ; 40(3): 581-587, 2023 Mar.
Article in English | MEDLINE | ID: mdl-36542313

ABSTRACT

PURPOSE: Infertility affects one in eight women in the USA. In vitro fertilization (IVF) is an effective but costly treatment that lacks uniform insurance coverage. We evaluated the current insurance coverage landscape for IVF in America. METHODS: We conducted a cross-sectional analysis of 58 insurance companies with the greatest state enrollment and market share, calculated to represent the majority of Americans with health insurance. Individual companies were evaluated for a publicly available policy on IVF services by web-based search, telephone interview, or email to the insurer. Coverage status, required criteria, qualifying risk factors, and contraindications to coverage were extracted from available policies. RESULTS: Fifty-one (88%) of the fifty-eight companies had a policy for IVF services. Thirty-five (69%) of these policies extended coverage. Case-by-case coverage was stated in seven policies (14%), while coverage was denied in the remaining nine (18%). The most common criterion to receive coverage was a documented diagnosis of infertility (n = 23, 66%), followed by care from a reproductive endocrinologist (n = 9, 26%). Twenty-three (45%) of the companies with a policy had at least one contraindication to coverage. Three companies (6%) limited the number of IVF cycles to be covered, capping payments after 3-4 lifetime cycles. CONCLUSION: Most Americans with health insurance are provided a public policy regarding IVF. However, there is great variation in coverage and requirements to receive coverage between insurers. Coupled with inconsistencies in state-level mandates and available choices for employer-sponsored plans, this may limit coverage of IVF services and, therefore, access to infertility treatment.


Subject(s)
Fertilization in Vitro , Infertility , Humans , Female , United States/epidemiology , Cross-Sectional Studies , Insurance, Health , Infertility/epidemiology , Infertility/therapy , Insurance Coverage
2.
Int J Gynecol Pathol ; 39(6): 567-572, 2020 Nov.
Article in English | MEDLINE | ID: mdl-31789679

ABSTRACT

Rare sex cord-stromal tumors of the ovary cannot be further subclassified and are therefore designated "sex cord-stromal tumor-not otherwise specified." These tumors have highly varied morphology, and the literature describing them is limited. Herein, we report the pathology and clinical course of a 46-yr-old woman diagnosed with sex cord-stromal tumor-not otherwise specified. The tumor was composed predominantly of juvenile granulosa cell tumor histology, with elements of thecoma, adult granulosa, Sertoli, as well as poorly differentiated epithelioid and sarcomatoid components. Next-generation sequencing revealed a FOXL2 C134W mutation, seen most commonly in adult granulosa cell tumors, as well as mutations in TP53 (V172F) and TERT promoter (-124C>T). The patient exhibited an aggressive clinical course involving rapid recurrence with distant metastases that responded to 4 cycles of cisplatin, bleomycin, and etoposide.


Subject(s)
Forkhead Box Protein L2/genetics , Mutation , Ovarian Neoplasms/genetics , Sex Cord-Gonadal Stromal Tumors/genetics , Tumor Suppressor Protein p53/genetics , Antineoplastic Combined Chemotherapy Protocols , Bleomycin/administration & dosage , Cisplatin/administration & dosage , Etoposide/administration & dosage , Female , Granulosa Cells/pathology , Humans , Middle Aged , Neoplasm Metastasis/drug therapy , Neoplasm Recurrence, Local/drug therapy , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/pathology , Promoter Regions, Genetic/genetics , Sex Cord-Gonadal Stromal Tumors/drug therapy , Sex Cord-Gonadal Stromal Tumors/pathology
3.
Gynecol Oncol Rep ; 23: 16-19, 2018 Feb.
Article in English | MEDLINE | ID: mdl-29326971

ABSTRACT

•A histologically low-grade cervical clear cell lesion was observed.•Proliferating cells were seen only at the periphery of this lesion.•Due to its low proliferation index, this may represent a precursor of clear cell carcinoma.•Further definition of such lesions may allow for more minimal management.

4.
J Neurodev Disord ; 8: 22, 2016.
Article in English | MEDLINE | ID: mdl-27303449

ABSTRACT

Induced pluripotent stem cells (iPSCs) allow researchers to make customized patient-derived cell lines by reprogramming noninvasively retrieved somatic cells. These cell lines have the potential to faithfully represent an individual's genetic background; therefore, in the absence of available human brain tissue from a living patient, these models have a significant advantage relative to other models of neurodevelopmental disease. When using human induced pluripotent stem cells (hiPSCs) to model X-linked developmental disorders or inherited conditions that undergo sex-specific modulation of penetrance (e.g., autism spectrum disorders), there are significant complexities in the course and status of X chromosome inactivation (XCI) that are crucial to consider in establishing the validity of cellular models. There are major gaps and inconsistencies in the existing literature regarding XCI status during the derivation and maintenance of hiPSCs and their differentiation into neurons. Here, we briefly describe the importance of the problem, review the findings and inconsistencies of the existing literature, delineate options for specifying XCI status in clonal populations, and develop recommendations for future studies.

5.
J Biol Chem ; 289(30): 20727-39, 2014 Jul 25.
Article in English | MEDLINE | ID: mdl-24920673

ABSTRACT

Centrioles play a key role in nucleating polarized microtubule networks. In actively dividing cells, centrioles establish the bipolar mitotic spindle and are essential for genomic stability. Drosophila anastral spindle-2 (Ana2) is a conserved centriole duplication factor. Although recent work has demonstrated that an Ana2-dynein light chain (LC8) centriolar complex is critical for proper spindle positioning in neuroblasts, how Ana2 and LC8 interact is yet to be established. Here we examine the Ana2-LC8 interaction and map two LC8-binding sites within the central region of Ana2, Ana2M (residues 156-251). Ana2 LC8-binding site 1 contains a signature TQT motif and robustly binds LC8 (KD of 1.1 µm), whereas site 2 contains a TQC motif and binds LC8 with lower affinity (KD of 13 µm). Both LC8-binding sites flank a predicted ~34-residue α-helix. We present two independent atomic structures of LC8 dimers in complex with Ana2 LC8-binding site 1 and site 2 peptides. The Ana2 peptides form ß-strands that extend a central composite LC8 ß-sandwich. LC8 recognizes the signature TQT motif in the first LC8 binding site of Ana2, forming extensive van der Waals contacts and hydrogen bonding with the peptide, whereas the Ana2 site 2 TQC motif forms a uniquely extended ß-strand, not observed in other dynein light chain-target complexes. Size exclusion chromatography coupled with multiangle static light scattering demonstrates that LC8 dimers bind Ana2M sites and induce Ana2 tetramerization, yielding an Ana2M4-LC88 complex. LC8-mediated Ana2 oligomerization probably enhances Ana2 avidity for centriole-binding factors and may bridge multiple factors as required during spindle positioning and centriole biogenesis.


Subject(s)
Drosophila Proteins/chemistry , Dyneins/chemistry , Multiprotein Complexes/chemistry , Protein Multimerization/physiology , Amino Acid Motifs , Animals , Cell Cycle Proteins , Drosophila Proteins/genetics , Drosophila Proteins/metabolism , Drosophila melanogaster , Dyneins/genetics , Dyneins/metabolism , Hydrogen Bonding , Multiprotein Complexes/genetics , Multiprotein Complexes/metabolism , Protein Binding , Protein Structure, Quaternary
SELECTION OF CITATIONS
SEARCH DETAIL
...